MicroBPlex
Industry: Immune-diagnostic platform
MicroBPlex is developing a diagnostic platform to identify microbial infections, particularly pneumonia and influenza. The diagnostic uses a matrix of newly synthesized antibodies that are secreted by specialized Antibody Secreting Cells (ASCs) that circulate in a patient’s blood during acute infections.
The novel platform promises to yield accurate testing results much earlier in the course of the infection, enabling doctors to administer faster, more effective treatment.
Pneumonia and Influenza continue to be serious health issues, particularly for the elderly. Together they are the sixth leading cause of death and the number one cause of deaths from infectious disease. Community Acquired Pneumonia (CAP) also affects 5.5 million patients in the U.S. each year, 1.1 million of whom require hospitalization.
